MedTrace Logo

Virtual Reality as a Tool to Lower Blood Pressure and Anxiety in Clinic Settings

NCT06960057 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2025-11-05

No results posted yet for this study

Summary

This clinical trial aims to evaluate whether a calming virtual reality (VR) experience can reduce office blood pressure (OBP) and anxiety in adults undergoing ambulatory blood pressure monitoring (ABPM) at Mayo Clinic in Florida.

The main questions it aims to answer are:

1. Does a 5-minute calming VR session reduce office blood pressure in patients with suspected white coat hypertension or white coat effect?
2. Does VR exposure reduce self-reported anxiety levels in the clinical setting?
3. Does VR reduce the difference between home (ABPM) and clinic blood pressure readings?

Participants will:

1. Complete two short electronic surveys (before and after VR exposure) on a clinic-provided device.
2. Undergo a 5-minute virtual reality (VR) relaxation session.
3. Have their blood pressure measured before and after the VR session.

Participation will occur during the participant's scheduled ABPM device return visit and will add approximately 30 minutes to the visit.

This is a single-arm, pre-post interventional study where each participant serves as their own control.

Conditions

  • White Coat Hypertension
  • Hypertension
  • Blood Pressure
  • Anxiety
  • Virtual Reality Exposure Therapy
  • Ambulatory Blood Pressure Monitoring
  • Blood Pressure Disorders

Interventions

BEHAVIORAL

Virtual Reality Exposure

Participants will be exposed to a standardized 5-minute virtual reality (VR) session using a commercially available VR headset. The session features a calming, immersive environment intended to reduce anxiety and lower office blood pressure (OBP) during a clinical visit. The VR experience is delivered after the return of an ambulatory blood pressure monitoring (ABPM) device and before the final BP measurements are obtained. Blood pressure and anxiety scores are assessed immediately before and after VR exposure.

Sponsors & Collaborators

Principal Investigators

  • Lyle W Baker, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-02
Primary Completion
2025-08-15
Completion
2025-08-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06960057 on ClinicalTrials.gov